A Patient with COVID-19 Pneumonia Who Developed Ventricular Fibrillation during Treatment with Hydroxychloroquine, Azithromycin and Favipiravir

DOI Web Site Web Site 11 References Open Access
  • OSHIMA Kazuhiro
    Department of Infection Control Science, Osaka City University Graduate School of Medicine
  • KUWAHARA Gaku
    Department of Infection Control Science, Osaka City University Graduate School of Medicine
  • IMOTO Waki
    Department of Infection Control Science, Osaka City University Graduate School of Medicine
  • YAMAIRI Kazushi
    Department of Infection Control Science, Osaka City University Graduate School of Medicine
  • SHIBATA Wataru
    Department of Infection Control Science, Osaka City University Graduate School of Medicine
  • YAMADA Koichi
    Department of Infection Control Science, Osaka City University Graduate School of Medicine
  • KIRITOSHI Ayako
    Department of Traumatology and Critical Care Medicine, Osaka City University Graduate School of Medicine
  • KAGA Shinichiro
    Department of Traumatology and Critical Care Medicine, Osaka City University Graduate School of Medicine
  • NISHIMURA Tetsuro
    Department of Traumatology and Critical Care Medicine, Osaka City University Graduate School of Medicine
  • MIZOBATA Yasumitsu
    Department of Traumatology and Critical Care Medicine, Osaka City University Graduate School of Medicine
  • KAKEYA Hiroshi
    Department of Infection Control Science, Osaka City University Graduate School of Medicine

Bibliographic Information

Other Title
  • ヒドロキシクロロキン，アジスロマイシン，ファビピラビルによる治療中に心室細動を起こした COVID-19 肺炎の1 例
  • 症例 ヒドロキシクロロキン,アジスロマイシン,ファビピラビルによる治療中に心室細動を起こしたCOVID-19肺炎の1例
  • ショウレイ ヒドロキシクロロキン,アジスロマイシン,ファビピラビル ニ ヨル チリョウ チュウ ニ シンシツサイドウ オ オコシタ COVID-19 ハイエン ノ 1レイ

Search this article

Description

<p>A 38-year-old man diagnosed as having COVID-19 pneumonia was transferred to our hospital from another hospital. The patient had received favipiravir at the previous hospital, and as he still had severe respiratory dysfunction, we added hydroxychloroquine and azithromycin to the treatment regimen for COVID-19 pneumonia at our hospital. The respiratory status improved gradually with the treatment and the patient began to be weaned from mechanical ventilation. However, on the 5th hospital day, the patient developed ventricular fibrillation (Vf) and cardiac arrest, with return of spontaneous circulation (ROSC) 2 minutes after the start of cardiopulmonary resuscitation. An electrocardiogram recorded after the ROSC showed not QT interval prolongation, but first-degree atrioventricular block. Nevertheless, because both hydroxychloroquine and azithromycin could cause QT interval prolongation, both were discontinued and the Vf did not recur. The patient was transferred to another hospital after extubation and had no neurological deficit. Herein, we report a patient with COVID-19 pneumonia who developed Vf while being treated with hydroxychloroquine,azithromycin and favipiravir.</p>

Journal

  • Kansenshogaku Zasshi

    Kansenshogaku Zasshi 94 (4), 600-603, 2020-07-20

    The Japanese Association for Infectious Diseases

References(11)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top